|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG|
|Immunogen||Purified recombinant fragment of SNCA expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 1 publications below|
MA5-15290 targets SNCA in Immunohistochemistry and Western Blot applications and shows reactivity with human samples.
The MA5-15290 immunogen is purified recombinant fragment of SNCA expressed in E. Coli.
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.
MA5-15290 was used in immunohistochemistry/immunofluorescence to demonstrate neuropathological diagnosis of Parkinson's disease.
|Sánchez-Danés A,Richaud-Patin Y,Carballo-Carbajal I,Jiménez-Delgado S,Caig C,Mora S,Di Guglielmo C,Ezquerra M,Patel B,Giralt A,Canals JM,Memo M,Alberch J,López-Barneo J,Vila M,Cuervo AM,Tolosa E,Consiglio A,Raya A||EMBO molecular medicine (4:380)||2012|